Blog: MARKER THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On September 13, 2022, Marker Therapeutics, Inc. (the “Company”) issued a press
release to announce that the U.S. Food and Drug Administration (the “FDA”) has
awarded the Company a $2.0 million grant from the FDA’s Orphan Products Grant
program to support the Company’s Phase 2 clinical trial of MT-401 for the
treatment of post-transplant AML. A copy of the press release is furnished
herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including
Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Number                              Exhibit Description
  99.1          Press Release, dated September 13, 2022.
104           The cover page from Marker Therapeutics, Inc.'s Form 8-K filed on
              September 13, 2022, formatted in Inline XBRL.

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s